Merck's (MRK) Investigational Migraine Treatment Improved Pain and Associated Symptoms in Phase III Study

June 27, 2008 11:06 AM EDT

Merck (NYSE: MRK) announced that in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo.

In addition, the efficacy results for telcagepant 300 mg were similar to the highest recommended dose of zolmitriptan,1 an approved migraine therapy, with a lower incidence of adverse events associated with telcagepant in this study. The new data were presented here at the American Headache Society (AHS) annual meeting.

This trial is part of an ongoing Phase III program evaluating telcagepant. While Phase II and Phase III trials have used a liquid-fill capsule (including the study presented here), telcagepant has been successfully reformulated into a solid tablet that is being evaluated in ongoing trials. Merck continues to anticipate filing a New Drug Application (NDA) for telcagepant with the U.S. Food and Drug Administration in 2009.[SM]

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?